#Bioretec #Finland #Helsinki #RemeOs #Kustaa Poutiainen

Important Changes at Bioretec Ltd

On May 8, 2026, Bioretec Ltd conducted a significant constitutive meeting of its Board of Directors following their Annual General Meeting. This event led to key appointments and discussions central to the duo's future direction.

Key Appointments

During this meeting, Kustaa Poutiainen was elected as the Chairperson of the Board, while David Gill took on the role of Deputy Chairperson. Their leadership is expected to steer the corporation towards innovative directions, particularly in the realm of orthopedic care.

In addition, committee members were appointed to strengthen oversight and governance:

• - Audit Committee: Led by Päivi Malinen, with members Michael Piccirillo and David Gill.
• - Remuneration Committee: Chaired by Justin Barad, including Antti Vasara and Michael Piccirillo.

These appointments reflect the company’s commitment to achieving robust governance standards and maintaining adherence to the Finnish Corporate Governance Code.

Independence Assessment

In accordance with the regulations, the Board assessed the independence of its members. Results showed that all members, except for Kustaa Poutiainen, are independent of Bioretec and its significant shareholders. Poutiainen is deemed independent of Bioretec itself but remains affiliated with a major shareholder, Stephen Industries Inc Oy, serving as their chairperson.

Focus on Innovation

Bioretec is recognized for its exceptional contributions to medical technology, especially in biodegradable implant technologies. As a pioneering Finnish company, they are dedicated to transforming orthopedic treatments through innovative implants designed to enhance bone growth while also facilitating recovery without the need for removal surgeries.

Their flagship product line, RemeOs™, utilizes a unique magnesium alloy and hybrid composite material that promotes stronger surgical outcomes. The groundbreaking implants absorb into the body and are replaced by bone tissue, showcasing a significant advancement in surgical materials and practices.

In March 2023, Bioretec was granted market authorization for RemeOs in the U.S., with subsequent CE marking approval achieved in January 2025 across Europe. Such approvals are crucial for Bioretec as they enhance their capacity to reach a broader market of patients in need of advanced orthopedic solutions.

Additionally, their Activa product line features fully bioabsorbable orthopedic implants made from a proprietary PLGA material that has already received both CE marking and FDA clearance, suitable for diverse applications involving both adult and pediatric patients.

Commitment to Patient-Centered Care

At the heart of Bioretec's mission is the pledge to focus on healing through absorption. Their innovative approach is set to elevate patient outcomes by providing safer and more comfortable solutions for surgical recovery. As the company continues to expand its reach across approximately 40 countries, Bioretec reinforces its stature within the medical device sector, ensuring that advanced orthopedic care is accessible worldwide.

For more information about Bioretec Ltd and its pioneering technologies, visit www.bioretec.com.

In summary, with the new appointments and a clear commitment to innovation, Bioretec Ltd is poised to become a leading force in the transformation of orthopedic surgery, reflecting a promising future for the industry and the patients they serve.